Welcome to the first-ever Derms on Drugs Debate! Our brave hosts tackle three of the hottest—and most controversial—questions in the field:

• Castle Gene Expression Profile in Melanoma: Should dermatologists use it for almost every melanoma, just those “close to 1 mm,” or leave it to the oncologists?

• Zoryve, VTAMA and Opzelura: All great drugs, but if you could only keep one, which would it be? Our hosts go head-to-head to defend their picks.

• The Next Game Changer in Dermatology: Will it be AI-powered skin cancer diagnosis, BTK inhibitors, or the first generic oral JAK? Hear our predictions and the cases for each.

Whether you’re a dermatology provider, researcher, or pharma professional, you’ll get expert insights, practical takeaways, and plenty of lively debate—Derms on Drugs style.

Tune in for clinical pearls, bold opinions, and a fresh look at the future of dermatology. Don’t miss out—hit play and join the debate!

Ready to level up your medical dermatology game? This week, Derms on Drugs tackles the toughest questions and latest controversies in serious derm—served with our signature practical, no-nonsense style with a big dose of humor.
We break down the newest literature and answer:
Does immunotherapy really help with high-risk squamous cell carcinoma?
Are pemphigus patients getting more rituximab than they need?
Why don’t JAK inhibitors increase cardiovascular risk in atopic dermatitis?
Is the Mind.Px test actually helpful for picking a psoriasis biologic?
What does drug level monitoring tell us about adalimumab in hidradenitis suppurativa?
Which treatment factors predict scabies cure?
Perfect for dermatology providers and industry pros who want clinical pearls, evidence-based answers, and a few laughs along the way. Tune in for the most fun you’ll have while getting smarter about serious medical derm!
Hit play and stay on the cutting edge of medical dermatology!

1. Adjuvant Cemiplimab or Placebo in HighRisk Cutaneous Squamous-Cell Carcinoma
2. Efficacy, safety, and B-cell depletion capacity of three rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial
3. Understanding Cardiovascular Events With JAK Inhibitors: Tofacitinib Reduces Synovial and Vascular Inflammation but not the Prothrombotic Effects of Inflammatory Cytokines on Endothelium
4. Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis
5. Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes
6. Therapeutic Drug Monitoring in Hidradenitis Suppurativa Patients With Suboptimal Treatment Response to Adalimumab
7. Scabies Management Outcomes: Identification of Risk Factors for Treatment Success or Failure

Chronic Spontaneous Urticaria (CSU) is back in the dermatology spotlight—and for good reason. Join the Derms on Drugs as we break down the latest clinical trial data on Dupixent (dupilumab) and the buzzworthy new oral BTK inhibitor, remibrutinib, both showing real promise for CSU patients who’ve hit a wall with antihistamines.
We’re joined by CSU expert Dr. Jason Hawkes to discuss:

-How Dupixent is changing the game for CSU and why dermatologists are leading the charge

-What makes remibrutinib “fast, sexy, and safe”—plus what the new Phase III data means for your patients

-How we explain to CSU patients that they don’t need allergy testing!

-Clinical pearls for work-up, navigating treatment guidelines, safety, and access

Perfect for derm providers who want the latest on CSU pathophysiology, emerging therapies, and patient communication. Tune in for actionable insights, expert commentary, and a dose of Derms on Drugs humor—because managing hives shouldn’t be a headache.

Hit play and stay ahead on the cutting edge of CSU care!

1. Autoimmune Thyroid Diseases in Chronic Spontaneous Urticaria: The Role of Hormones, Anti-Thyroid Antibodies, and Ultrasound

2. Remibrutinib in Chronic Spontaneous Urticaria

3. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

Ready to stay ahead in dermatology? Join the Derms on Drugs for a fast-paced, practical dive into the hottest new research and trends shaping our specialty.

This week, we break down:

• Surprising long-term data comparing Dupixent and Rinvoq for atopic dermatitis

• The future of autoimmune disease treatment: genetically modified T cells

• What policies people actually support (and will pay for) to reduce skin cancer rates

• JAK inhibitors for mucosal pemphigoid—what’s new, what works, and what to watch for

• The latest on rising contact allergens: which ones are on the move and why

Packed with clinical pearls, practical tips, and a dash of humor, this episode is your shortcut to what’s new, what’s changing, and what you can use in practice right now.

Don’t miss out—hit play for your weekly dose of dermatology insights!

For links to all articles visit ScholarsinMedicine.com

1. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study
2. Janus Kinase Inhibitors in the Treatment of Refractory Cicatrizing Conjunctivitis in Pemphigoid
3. Long-Term Real-World Effectiveness of Dupilumab vs. Upadacitinib in early Treatment Responders with Atopic Dermatitis: Results from Central European Health Fund Registry
4. Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study
5. Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents
6. Public preferences for skin cancer prevention policies: a discrete choice experiment in three European countries
7. North American Contact Dermatitis Group Patch Test Results: 2021–2022

Ever feel overwhelmed by the flood of alopecia treatments and supplements?

Join the Derms on Drugs as we cut through the noise with Dr. Michelle Tarbox, diving deep into the practical side of managing alopecia for dermatology providers.

In this episode, we tackle:

• Which labs to order for telogen effluvium
• Which hair loss supplements are actually worth recommending
• The truth about red light helmets
• How and when to use prescription therapies for hair loss
• Can shampoo really help with alopecia?

Tune in for expert insights, practical tips, and a healthy dose of humor—perfect for medical providers who want to stay ahead in dermatology without getting lost in the latest hype.

Listen now for all the answers—and maybe a few laughs!

Hair loss is common and devastating, both to the person losing their hair and the dermatology provider taking care of them. Derms on Drugs to the rescue. In part one of our deep dive into hair loss we cover three big topics: 1) What supplements for hair loss actually work? You'll have heard (ad nauseum) about some of them, but we'll also bring you some ideas for cheap supplements you haven't heard of that actually work; 2) Do we really need to do lab work-ups in patients with telogen effluvium? and 3) What's the state of the art when it comes to diagnosing and managing folliculitis decalvans? Join us for another episode with our trademark mix of evidence and banter! #DermatologyPodcast #HairLoss #DermsOnDrugs #Alopecia

Produced by ScholarsinMedicine.com

ScholarsinMedicine.com⁠

1. Management of folliculitis decalvans: The EADV task force on hair diseases position statement
2. Retrospective Review of 2851 Female Patients With Telogen Effluvium: A Single-Center Experience
3. Impact of Laboratory Work Up and Supplementation on Alopecia Patients: A Single-Center Retrospective Chart Review
4. Evaluation of the Safety and Effectiveness of Nutritional Supplements for Treating Hair Loss A Systematic Review

Join Derms on Drugs for a must-hear episode packed with practical dermatology updates!

Discover if Nutrafol Acne delivers, which skin care ingredients top cosmetic dermatologists swear by, and the latest breakthroughs for hand eczema. Plus, is Zoryve Foam a game-changer for psoriasis? And what’s the deal with PRAME staining for benign nevi? Get actionable insights to elevate your practice along with our usual banter.

Derms on Drugs is produced by Scholars in Medicine.

Resource links can be found at: Scholarsinmedicine.com
1. A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial for the Efficacy and Safety of a Novel Nutraceutical for Mild-to-Moderate Acne
2. Skincare Ingredients Recommended by Cosmetic Dermatologists: A Delphi Consensus Study
3. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial
4. Oral roflumilast for the treatment of chronic hand eczema: a retrospective case series
5. Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body
6. Clinicopathologic Features of PRAME-Positive Common Melanocytic Nevi: A Case-Control Study

Skyrocketing drug prices are hitting dermatology hard. Why are Americans paying more than other countries? Are Pharmacy Benefit Managers (PBMs) or pharmaceutical companies to blame? Join Derms on Drugs as our experts pull back the curtain on the broken system driving costs. Get insider insights, practical takeaways, and our trademark banter to navigate this mess as a clinician.

Derms on Drugs is a production of Scholarsinmedicine.com

1. Use and Cost of First-Line Biologic Medications to Treat Plaque Psoriasis in the US
2. Systematic review and estimated cost-efficacy of biologics compared with narrowband ultraviolet B light for the treatment of moderate to severe psoriasis and atopic dermatitis
3. AI Description and Answers About How Drug Pricing Works

Scholarsinmedicine.com